secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001082554-25-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough
--------------------------------------------------------------------------------

- Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.
- Tyvaso DPI sales $336.2M (+22% YoY) driving total Tyvaso growth to $478M (+10%).
- Orenitram $131.1M (+16%); Unituxin $47.9M (-22%) offset by price increases.
- TETON-2 study in IPF shows breakthrough results; could significantly broaden therapeutic reach.
- Entered $1B accelerated share repurchase in Aug 2025; received 2.6M shares in Q3 (combined $2B since Mar 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/0001082554-25-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255425000036/uthr-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001082554-25-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer